| abstract |
There are disclosed methods of use and pharmaceutical compositions for two related fenera of low molecular weight compounds comprising optionally substituted iminoquinone or orthoquinone ring systems. The compounds have MI F (macrophage migration inhibitory factor) antagonist activity and find utilit y as such. For example, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatiod arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, EAE, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular diseases, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis). |